The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks.
Abstract
PSMA-based radioligand therapies have shown the beneficial effect in metastatic castrate-resistant prostate cancer (mCRPC) patients when they become refectory to the established treatments with associated potential toxicities and high mortality rate. Ac-PSMA therapy is known to be remarkably effective in substantially pretreated mCRPC patients. However, posttherapy imaging is usually not performed as alpha emitters are really difficult to image. We presents a patient of mCRPC treated with Ac-PSMA-617, and his posttherapy whole-body scans acquired by using 3 different photopeaks (78, 218, and 440 keV) fairly demonstrated the tracer's distribution and the efficacy of targeted alpha therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the literature showing the feasibility of using the three photopeaks is limited to only few clinical case reports (108, 109).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [109]
Citations
Cites
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229229 · Cited by 196
The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides
Ackerman, N. L., & Graves, E. E. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/3/771 · Cited by 46
225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks
Usmani, S., Rasheed, R., Al kandari, F., Marafi, F., & Naqvi, S. A. R. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002525 · Cited by 35
Rasheed, R., Usmani, S., Raza Naqvi, S., Alkandari, F., & Marafi, F. (2019) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_115_18 · Cited by 11
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Metadata
- Authors
- Vatsa, R., Sood, A., Vadi, S. K., Das, C. K., Kaur, K., Parmar, M., & Mittal, B. R.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Department of Nuclear Medicine, Nehru Hospital
- Corresponding author
- Vatsa, Rakhee
- Sood, Ashwani
- Vadi, Shelvin Kumar
- Kaur, Komalpreet
- Parmar, Madan
- Mittal, Bhagwant Rai
- Venue
- Clinical Nuclear Medicine
- Published
- 2020-06
- Volume
- 45
- Issue
- 6
- Pages
- 437-438
- ISSN
- 0363-9762 (ISSN-L)
- 1536-0229
- OpenAlex
- W3023299268
- Cited by
- 23
- References
- 7
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 1 · 2020: 1
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic castration-resistant prostate cancer, targeted alpha therapy, whole-body scintigraphy, PSMA radioligand therapy, previously treated patients
- MeSH terms
- Actinium, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Ligands, Male, Neoplasm Metastasis, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
